The warrant expiration removes a potential overhang of ~4.1% dilution at the $16 strike, which is now moot. Monitor for any insider selling or open-market purchases by Auerbach in the coming weeks, as the filing notes no transactions in the past 60 days.
Price Chart
Executive Summary
Alan H. Auerbach, CEO and President of Puma Biotechnology, filed an amended Schedule 13D reporting that his 2011 warrant to purchase 2,116,250 shares of common stock at $16.00 per share expired unexercised on October 4, 2026. His beneficial ownership decreased from a prior level that included the warrant to 8,648,958 shares (16.0% of outstanding common stock), reflecting the warrant expiration. The filing is a routine administrative update with no change in his intentions or demands.
Key Financial Metrics
Key Facts
- Warrant to purchase 2,116,250 shares of common stock at $16.00 per share expired unexercised on October 4, 2026.
- Alan H. Auerbach beneficially owns 8,648,958 shares of common stock, representing approximately 16.0% of outstanding shares.
- Ownership includes 6,400,295 shares held directly, 1,556,721 shares issuable upon exercise of vested stock options, and 691,942 shares issuable upon vesting of restricted stock units within 60 days.
- Percentage ownership based on 51,698,356 shares outstanding as of October 5, 2026.
- No change in stated purpose or plans; Auerbach remains CEO and director with no new demands or intentions.
Financial Impact
No financial impact. The warrant expired worthless, eliminating potential dilution of up to 2,116,250 shares.
Risk Factors
- No material risks identified from this filing; it is a routine administrative update.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001104659-26-114167 |
| Document: 0001104659-26-114167-index.html | 0001104659-26-114167 |
| Document: 0001104659-26-114167.txt | 0001104659-26-114167 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13D/A | $9.81 | awaiting T+20 | — | $10.85 (+10.60%) |
Sep 16, 2026 5w ago | Insider Cluster | $9.52 $10.52 | ▼ −10.50% | ▼ −9.30% | $10.85 (−13.97%) |
Jul 8, 2026 15w ago | Insider Cluster | $7.90 $8.12 | ▲ +2.78% | ▲ +0.54% | $10.85 (+37.34%) |
Jul 6, 2026 16w ago | 144 | $7.96 $7.69 | ▼ −3.39% | ▼ −4.72% | $10.85 (+36.31%) |
Jun 15, 2026 19w ago | Insider Cluster | $7.17 $8.28 | ▲ +15.48% | ▲ +15.28% | $10.85 (+51.32%) |
Jun 12, 2026 19w ago | 144 | $7.33 $8.00 | ▲ +9.14% | ▲ +7.36% | $10.85 (+48.02%) |
Feb 26, 2026 34w ago | 8-K | $5.70 $6.08 | ▲ +6.67% | ▲ +14.22% | $10.85 (+90.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers